Drug Profile

Baclofen extended release - Indaptus Therapeutics

Alternative Names: Accordian pill baclofen; AP-Baclofen; Baclofen GR

Latest Information Update: 19 Dec 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Intec Pharma
Class Aminobutyric acids; Antispastics; Muscle relaxants; Small molecules
Mechanism of Action GABA B receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

No development reported Muscle spasticity

Most Recent Events

03 Aug 2021 Decoy Biosystems has merged with Intec Pharma to form Indaptus Therapeutics
28 Apr 2020 No recent reports of development identified for phase-I development in Muscle-spasticity in Israel (PO, Controlled release)
15 Apr 2020 Intec Pharma has several patents and applications related to its Accordion Pill technology, in several countries worldwide

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com